# A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

> **NCT05930925** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [phenyl-14C]ARV-471
- **DRUG:** [oxoisoindolin-14C]ARV-471

## Key facts

- **NCT ID:** NCT05930925
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-12
- **Primary completion:** 2023-07-27
- **Final completion:** 2023-08-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930925, "A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05930925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*